Alcon Acquired by Novartis
On December 15, 2010, Novartis (NYSE: NVS) agreed to acquire the remaining shares of Alcon, Inc. (NYSE: ACL) it doesn't currently own for $168 per share.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
-
Lpath Adds Two Key Members to its Executive Team
-
The Agency Inside Harte-Hanks and Alcon Laboratories to Present at Forrester Marketing Forum
-
Alcon Launches a New Mobile Website to Educate Parents About Commonly Prescribed Eye and Ear Treatments
-
Kala Pharmaceuticals Appoints Kim Brazzell, Ph.D., as Chief Medical Officer
-
Novartis' (NVS) Alcon Receives Positive CHMP Opinion for Jetrea as VMT Treatment
-
Novartis' (NVS) Unit Gets Exclusive Rights to Ocriplasmin Outside the U.S.
-
Novartis (NVS) Misses Q3 EPS by 6c, Sales Miss Expectations, Offers Q4 Outlook
-
Novartis (NVS) Updates on Long-Term Strategy; Comments on Plans for Alcon
-
Top 10 News Items 12/13-12/17: $858B Tax-Cut Bill Signed; Best Buy Tanks on Concerning Q3 Results; Visa, MasterCard Tumble As Durbin Strikes Back
